![Daniel E. Spratt: It is a huge honor to be the 1st radonc as a full standing member on the FDAs ODAC (I am at least told).](https://oncodaily.com/pub/uploads/2023/10/download-35-1195x1280.jpg)
Daniel E. Spratt: It is a huge honor to be the 1st radonc as a full standing member on the FDAs ODAC (I am at least told).
Daniel E. Spratt, Chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center, recently shared a post by Jorge Garcia on X/Twitter, adding:
“It is a huge honor to be the 1st radonc as a full standing member on the FDAs ODAC (I am at least told). Will try to fill 1% of Jorge Garcia who did an amazing job as as Chair. Time for my odd obsession in biostats, surrogate endpoints, futility analyses, trial design and wanting to help reduce suffering from cancer to be put to hopefully good use on a new level.”
Quoting Jorge Garcia’s post:
“Delighted to see our own Daniel E. Spratt as a new standing committee member for our FDA Oncology Drug Advisory Committee (ODAC). The beginning of a tradition- future Chair?”
Source: Daniel E. Spratt/Twitter and Jorge Garcia/Twitter